Related Experiment Videos
[Competitive new generation myorelaxants in pediatric neuroanesthesia]
D Gifuni1, A Frangiosa, A Geri
1Sezione di Neuroanestesia, USL n. 40, Ospedale Santobono, Napoli.
Minerva Anestesiologica
|April 1, 1992
Summary
Atracurium and vecuronium, neuromuscular blocking drugs, showed shorter onset and longer duration in newborns and infants. Subsequent doses had similar effects across age groups, highlighting monitoring importance.
Area of Science:
- Anesthesiology
- Pediatric Pharmacology
Background:
- Neuromuscular blocking drugs (NMBDs) are essential in pediatric anesthesia.
- Understanding age-specific pharmacokinetics of NMBDs like atracurium and vecuronium is crucial for safe and effective use.
Purpose of the Study:
- To compare the clinical use of atracurium and vecuronium in pediatric patients.
- To evaluate the onset time and clinical duration of these neuromuscular blocking drugs across different pediatric age groups.
Main Methods:
- A study involving two groups of 50 children each.
- Administration and monitoring of atracurium and vecuronium.
- Analysis of onset time and clinical duration of initial and subsequent doses.
Main Results:
- Newborns and infants exhibited a shorter onset time and longer clinical duration for the initial dose of both atracurium and vecuronium.
- The duration of subsequent doses did not significantly differ among the various age groups.
- Both drugs demonstrated a short recovery index, maintained cardiovascular stability, and did not impact intracranial pressure (ICP).
Conclusions:
- Atracurium and vecuronium are effective neuromuscular blocking agents in pediatric patients.
- Age-specific dosing considerations, particularly for initial doses in neonates and infants, are important.
- Continuous monitoring of neuromuscular blockade is emphasized for safe administration in children.